anlotinib + capecitabine + gimeracil + oteracil + oxaliplatin + tegafur

This combination therapy is an investigational regimen being evaluated as adjuvant treatment for locally advanced gastrointestinal tumors, specifically gastric and colorectal cancers, following radical resection. It combines **anlotinib**, a multi-target tyrosine kinase inhibitor that suppresses tumor angiogenesis and growth by targeting VEGFR, FGFR, PDGFR, and c-Kit, with standard cytotoxic chemotherapy protocols. The chemotherapy component consists of either **CAPEOX** (capecitabine and oxaliplatin) or **SOX** (S-1 and oxaliplatin). S-1 is a fixed-dose combination of **tegafur** (a 5-fluorouracil prodrug), **gimeracil** (a dihydropyrimidine dehydrogenase inhibitor that prevents 5-FU degradation), and **oteracil** (which reduces gastrointestinal toxicity). **Oxaliplatin** acts as a platinum-based DNA cross-linking agent, while **capecitabine** and tegafur inhibit thymidylate synthase to disrupt DNA synthesis. This multi-modal approach aims to improve disease-free survival by simultaneously targeting tumor cell proliferation and the supporting vascular microenvironment.

Other names

anlotinib + capecitabine + gimeracil + oteracil + oxaliplatin + tegafur-Xijing Hospital-gastric cancer-colorectal canceranlotinib + CAPEOXanlotinib + SOXanlotinib + S-1 + oxaliplatin